Loss of MNX1 Sensitizes Tumors to Cytotoxic T Cells by Degradation of PD‐L1 mRNA

Loss of MNX1 Sensitizes Tumors to Cytotoxic T Cells by Degradation of PD‐L1 mRNA

Abstract Immune checkpoint blockade (ICB) therapy, targeting programmed cell death ligand‐1 (PD‐L1)/programmed cell death protein 1 (PD‐1) axis and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), has exhibited amazing clinical outcomes in various types of cancers. However, only a small portion...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhengzheng Li, Lei Chen, Ge Zhang, Shuang Wang, Enhang Xu, Jinglei Teng, Jiancheng Xu, Fang Peng, Qingjie Min, Zhuoya Wang, Shujuan Shao, Lianmei Zhao, Baoen Shan, Yang Wang, Qimin Zhan, Xuefeng Liu
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:Advanced Science
Subjects:
immunotherapy
MNX1
MNX1‐AS1
PD‐L1
tumor immune escape
Online Access:https://doi.org/10.1002/advs.202403077
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Immune checkpoint blockade (ICB) therapy, targeting programmed cell death ligand‐1 (PD‐L1)/programmed cell death protein 1 (PD‐1) axis and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), has exhibited amazing clinical outcomes in various types of cancers. However, only a small portion of patients benefit from ICB therapy, indicating that the mechanism underlying immune checkpoint is still unclear. Here, it is reported that motor neuron and pancreas homeobox 1 (MNX1), a homeobox domain‐containing transcription factor, contributes to the tumor immune escape. MNX1 increases PD‐L1 expression in cancer cells by stabilizing PD‐L1 mRNA rather than activating transcription. Mechanistically, MNX1 exists in the cytoplasm of cancer cells and interacts with Y‐box binding protein 1 (YBX1), a multifunctional DNA/RNA‐binding protein, to enhance the binding of YBX1 to PD‐L1 mRNA. MNX1 ablation activates cytotoxic T cell‐mediated anti‐tumor immunity and sensitizes CTLA‐4 blockade therapy. Moreover, MNX1 also facilitates tumor progression in an immune‐independent manner in cancer cells. In addition, MNX1 is upregulated by its adjacent long non‐coding RNA MNX1‐AS1 via HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2). Together, these results reveal MNX1 as a novel immune checkpoint regulator with promising therapeutic potential.
ISSN:2198-3844

Similar Items